返回
Invasive Candidiasis
DOI:10.1016/j.idc.2024.11.007.png)
摘要
En 中文
Candida is a leading cause of hospital-acquired bloodstream infections, particularly in patients admitted to intensive care units. Nonculture-based molecular diagnostic assays improve time to treatment, thereby potentially influencing morbidity and mortality. Echinocandins are the treatment of choice for most cases of invasive candidiasis (IC) that do not involve the central nervous system and/or the eyes. Targeted antifungal prophylaxis decreases rates of IC and may influence mortality. Candida auris represents an emerging public health concern worldwide due to its inherent antifungal resistance and lethality, and its ability to persist on inanimate material.
Keyword:
Candida
Invasive candidiasis
Antifungals
Bloodstream infection
Fungal infection
期刊
IF:
4.1
论文数:
1.7K
被引数:
4.5K
机构
引用论文
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
LANCET
IF88.5
CULTURE-NEGATIVE CANDIDA MENINGITIS DIAGNOSED BY DETECTION OF CANDIDA MANNAN ANTIGEN IN CSF
NEUROLOGY
IF8.5
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses通过全基因组测序和流行病学分析证实了三大洲同时出现多药耐药的耳念珠菌


